Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars
Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
Colorectal cancer (CRC) is a leading cause of tumor-related morbidity and mortality worldwide, with mortality most often attributable to metastatic disease. Bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor, has a significant role in the treatment of metastatic CRC (mCRC). However, patient access to bevacizum...
Alternative Titles
Full title
Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5610666
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5610666
Other Identifiers
ISSN
1776-2596
E-ISSN
1776-260X
DOI
10.1007/s11523-017-0518-1
